BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insider Henry J. Fuchs sold 15,000 shares of BioMarin Pharmaceutical stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $89.23, for a total value of $1,338,450.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded up $0.03 during midday trading on Friday, reaching $90.35. The company’s stock had a trading volume of 247,399 shares, compared to its average volume of 1,160,000. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41. The company has a market cap of $15,900.00, a P/E ratio of -108.86 and a beta of 1.81. BioMarin Pharmaceutical Inc. has a 52 week low of $80.10 and a 52 week high of $100.51.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings data on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $334.18 million for the quarter, compared to analysts’ expectations of $347.38 million. BioMarin Pharmaceutical had a negative return on equity of 4.60% and a negative net margin of 12.45%. BioMarin Pharmaceutical’s quarterly revenue was up 19.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.02 earnings per share. sell-side analysts expect that BioMarin Pharmaceutical Inc. will post -0.64 earnings per share for the current year.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Goldman Sachs Group reissued a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a research note on Friday, October 6th. Morgan Stanley restated an “overweight” rating and set a $117.00 price objective (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Jefferies Group restated a “buy” rating and set a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Tuesday, September 26th. Finally, BidaskClub upgraded BioMarin Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 16th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. BioMarin Pharmaceutical currently has an average rating of “Buy” and an average price target of $112.44.

A number of hedge funds have recently made changes to their positions in the stock. Atlantic Trust Group LLC acquired a new position in BioMarin Pharmaceutical in the third quarter worth $1,997,000. Americafirst Capital Management LLC acquired a new position in BioMarin Pharmaceutical in the third quarter worth $702,000. IFM Investors Pty Ltd acquired a new position in BioMarin Pharmaceutical in the third quarter worth $448,000. Piedmont Investment Advisors LLC acquired a new position in BioMarin Pharmaceutical in the third quarter worth $561,000. Finally, California Public Employees Retirement System boosted its stake in BioMarin Pharmaceutical by 1.6% in the third quarter. California Public Employees Retirement System now owns 332,500 shares of the biotechnology company’s stock worth $30,946,000 after purchasing an additional 5,100 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/01/05/biomarin-pharmaceutical-inc-bmrn-insider-henry-j-fuchs-sells-15000-shares.html.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.